SU2C research leads to FDA approval of new first-line treatment for colorectal cancer

(Stand Up To Cancer) The FDA recently approved the immunotherapy drug pembrolizumab as a first-line treatment for patients with certain types of advanced colorectal cancer. This is the 9th FDA approval supported by Stand Up To Cancer ® (SU2C) research. Patients newly diagnosed with advanced or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer previously would have been prescribed pembrolizumab only after exhausting standard chemotherapy treatments.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news